Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression
Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression
复制标题
DOI：
10.1007/s13277-012-0499-8
复制
发表时间：
2012-09
期刊：
影响因子：
--
通讯作者：
S. Yamashita;K. Tokuishi;T. Moroga;Satoshi Yamamoto;K. Ohbo;S. Miyahara;Y. Yoshida;J. Yanagisawa;D. Hamatake;M. Hiratsuka;Y. Yoshinaga;T. Shiraishi;A. Iwasaki;K. Kawahara
中科院分区：
文献类型：
--
作者：
S. Yamashita;K. Tokuishi;T. Moroga;Satoshi Yamamoto;K. Ohbo;S. Miyahara;Y. Yoshida;J. Yanagisawa;D. Hamatake;M. Hiratsuka;Y. Yoshinaga;T. Shiraishi;A. Iwasaki;K. Kawahara
人附睾四号(HE4)蛋白在附睾和呼吸道中表达。我们曾报道HE4在肺腺癌中也有表达。本研究的目的是探讨肺腺癌患者血清HE4水平的变化。作为训练集，对2008-2011年间在我所接受手术的102例肺腺癌患者进行评估。并与58例健康体检者和16例肺部良性疾病患者进行比较。在验证中，我们使用了2000年至2007年间接受手术的104名肺腺癌患者。本文观察了35例患者术后血清HE4水平的变化。用酶免疫测定法测定HE4水平，并与临床病理因素进行比较。在训练组中，肺腺癌患者血清HE4水平显著高于健康对照组和良性肺病患者。受试者工作特征曲线显示HE4对肺腺癌有较好的鉴别诊断价值(临界点为50.3 pm；曲线下面积为0.825；95%可信区间0.76~0.89，p<； 为0.001)。在验证组中，血清HE4水平与年龄、结节状况和癌胚抗原显著相关。此外，术后血清HE4水平升高与复发显著相关(p= 0.032)。HE4阳性组5年总生存率为52.6%，而HE4阴性组为97.1%(p= 0.001)。提示HE4在血清中的表达与肺腺癌的进展有关，可能是肺腺癌的一个生物标志物。
The human epididymis 4 (HE4) protein is expressed in the epididymis and respiratory tract. We previously reported that HE4 is also expressed in pulmonary adenocarcinoma. The purpose of this study was to investigate serum levels of HE4 as a biological marker in pulmonary adenocarcinoma. As the trained set, 102 patients with pulmonary adenocarcinoma who underwent surgery in our institute from 2008 to 2011 were evaluated. They were compared with 58 healthy controls and 16 cases of benign lung disease. In the validation, we used 104 patients with pulmonary adenocarcinoma operated on between 2000 and 2007. Postoperative changes of serum HE4 levels were investigated in 35 patients. The level of HE4 was determined by enzyme immunometric assay and compared with clinicopathological factors. In the trained set, HE4 levels in sera in pulmonary adenocarcinoma were significantly higher than in healthy controls and benign lung disease. Receiver operating characteristic curve showed that HE4 was a good discriminator of pulmonary adenocarcinoma (cut-off point, 50.3 pM; area under curve, 0.825; 95 % confidence interval, 0.76–0.89,p< 0.001). In the validation set, serum HE4 levels were significantly correlated with age, nodal status, and carcinoembryonic antigen. Furthermore, postoperative increase of HE4 serum levels showed a significant correlation with recurrence (p= 0.032). The 5-year overall survival rate was 52.6 % in the HE4-positive group compared with 97.1 % in the HE4-negative group (p= 0.001). These data showed that HE4 expression in sera is associated with progression of pulmonary adenocarcinoma and a possible biomarker.